Hologic, Inc. (HOLX)

Market Cap	16.26B
Revenue (ttm)	4.03B
Net Income (ttm)	789.50M
Shares Out	226.94M
EPS (ttm)	3.32
PE Ratio	21.58
Forward PE	16.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,640,784
Open	70.70
Previous Close	70.76
Day's Range	70.36 - 71.95
52-Week Range	70.36 - 84.67
Beta	0.96
Analysts	Buy
Price Target	89.50 (+24.91%)
Earnings Date	Jan 30, 2025

About HOLX

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginos...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jun 21, 1990
• Employees: 6,990
• Stock Exchange: NASDAQ
• Ticker Symbol: HOLX
• Website: https://www.hologic.com

Financial Performance

In 2024, Hologic's revenue was $4.03 billion, a decrease of -0.00% compared to the previous year's $4.03 billion. Earnings were $789.50 million, an increase of 73.14%.

Analyst Forecast

According to 13 analysts, the average rating for HOLX stock is "Buy." The 12-month stock price forecast is $89.5, which is an increase of 24.91% from the latest price.

Price Target

$89.5

(24.91% upside)

Analyst Consensus: Buy